[go: up one dir, main page]

TN2009000136A1 - Sequential combination therapy - Google Patents

Sequential combination therapy

Info

Publication number
TN2009000136A1
TN2009000136A1 TNP2009000136A TN2009000136A TN2009000136A1 TN 2009000136 A1 TN2009000136 A1 TN 2009000136A1 TN P2009000136 A TNP2009000136 A TN P2009000136A TN 2009000136 A TN2009000136 A TN 2009000136A TN 2009000136 A1 TN2009000136 A1 TN 2009000136A1
Authority
TN
Tunisia
Prior art keywords
combination therapy
sequential combination
angiogenesis
related disorders
administration
Prior art date
Application number
TNP2009000136A
Other languages
English (en)
Inventor
Rakesh K Jain
Clive R Wood
Daniel T Dransfield
Antonio Arulanandam
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of TN2009000136A1 publication Critical patent/TN2009000136A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TNP2009000136A 2006-10-17 2009-04-13 Sequential combination therapy TN2009000136A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85226306P 2006-10-17 2006-10-17
US87573606P 2006-12-19 2006-12-19
PCT/US2007/081621 WO2008048996A2 (fr) 2006-10-17 2007-10-17 Thérapie de combinaison séquentielle

Publications (1)

Publication Number Publication Date
TN2009000136A1 true TN2009000136A1 (en) 2010-10-18

Family

ID=39314809

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000136A TN2009000136A1 (en) 2006-10-17 2009-04-13 Sequential combination therapy

Country Status (17)

Country Link
US (1) US20080160019A1 (fr)
EP (1) EP2073826A4 (fr)
JP (1) JP2010506951A (fr)
KR (1) KR20090067214A (fr)
AU (1) AU2007311092A1 (fr)
BR (1) BRPI0717760A2 (fr)
CA (1) CA2666714A1 (fr)
CR (1) CR10798A (fr)
EA (1) EA200900562A1 (fr)
EC (1) ECSP099336A (fr)
IL (1) IL198026A0 (fr)
MA (1) MA30901B1 (fr)
MX (1) MX2009004070A (fr)
NI (1) NI200900057A (fr)
NO (1) NO20091375L (fr)
TN (1) TN2009000136A1 (fr)
WO (1) WO2008048996A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004266242A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
WO2005107461A2 (fr) * 2004-04-07 2005-11-17 The General Hospital Corporation Modulation de la fonction lymphatique
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
EP2156834A1 (fr) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Compositions pharmaceutiques ophtalmiques comprenant du Sorafenib pour le traitement de pathologies néoangiogéniques de l'ýil
WO2011121560A2 (fr) * 2010-03-31 2011-10-06 Universite De Geneve Préparations d'anticorps stabilisés et utilisations correspondantes
US9804675B2 (en) 2013-06-27 2017-10-31 Elwha Llc Tactile feedback generated by non-linear interaction of surface acoustic waves
US20150003204A1 (en) * 2013-06-27 2015-01-01 Elwha Llc Tactile feedback in a two or three dimensional airspace

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
AU2004266242A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1789451A4 (fr) * 2004-08-12 2009-12-02 Dyax Corp Protéines de liaison au complexe tie
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
CA2666714A1 (fr) 2008-04-24
WO2008048996A2 (fr) 2008-04-24
NI200900057A (es) 2010-02-02
US20080160019A1 (en) 2008-07-03
ECSP099336A (es) 2009-06-30
BRPI0717760A2 (pt) 2013-11-12
JP2010506951A (ja) 2010-03-04
CR10798A (es) 2009-06-09
EP2073826A2 (fr) 2009-07-01
EA200900562A1 (ru) 2009-10-30
NO20091375L (no) 2009-07-10
MA30901B1 (fr) 2009-11-02
MX2009004070A (es) 2009-04-27
WO2008048996A9 (fr) 2008-09-12
KR20090067214A (ko) 2009-06-24
EP2073826A4 (fr) 2010-12-15
AU2007311092A1 (en) 2008-04-24
IL198026A0 (en) 2011-08-01
WO2008048996A3 (fr) 2008-07-03

Similar Documents

Publication Publication Date Title
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
TN2009000136A1 (en) Sequential combination therapy
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
WO2008095086A3 (fr) Topiramate plus naltrexone pour le traitement de troubles addictifs
EP2059282A4 (fr) Appareil, procédés et dispositifs pour le traitement de troubles oculaires
IL207688A0 (en) Methods of treating skin disorders using an il-31ra antagonist
BRPI0922823A2 (pt) Combinações e modos de administração de agentes terapêuticos e terapia de combinação
IL196612A0 (en) Therapeutic methods for treating vascular eye disorders with dll4 antagonists
MX2007008756A (es) Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
WO2008073509A3 (fr) Compositions et procédés de traitement d'un néoplasme
WO2010014595A3 (fr) Méthodes et compositions d'administration d'agents thérapeutiques dans le traitement de troubles associés aux lymphocytes b
IL201422A0 (en) Therapeutic agents useful for treating pain
IL198723A0 (en) Methods and compositions for therapeutic treatment
WO2009068659A3 (fr) Nouveau traitement de maladies par prédiction d'association médicamenteuse
MY160406A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
IL200525A0 (en) Methods of treating cancer by administering human il-18 combinations
WO2008089070A3 (fr) Polythérapie pour le traitement du cancer
TN2009000490A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
IL206435A0 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств